The Scottish Medicines Consortium (SMC) recently published advice pertaining to the acceptance of two new therapies for use by NHS Scotland.
Fremanezumab (Ajovy) has been accepted for the prophylaxis of migraine in adults having at least four migraine days per month. The use of fremanezumab has been restricted only to patients with chronic and episodic migraine who have been previously unresponsive to ≥3 migraine preventive treatments. Evidence from phase III studies showed fremanezumab to be superior to placebo in decreasing the number of monthly migraine days in patients with chronic and episodic migraine.
Ocrelizumab (Ocrevus) has been accepted for the treatment of adults with early primary progressive multiple sclerosis (PPMS) defined by disease duration and disability level, and with imaging features indicating inflammatory activity. Evidence from a double-blind, phase III study showed a significantly lower risk for disability progression in patients treated with ocrelizumab vs placebo.
The SMC advice considers the benefits of a 'Patient Access Scheme' that improves the cost-effectiveness of fremanezumab and ocrelizumab.